Cancer News and Research

Latest Cancer News and Research

Amorfix Life Sciences signs sale and distribution agreement with Cedarlane Laboratories

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, announced today that it has signed an agreement with Cedarlane Laboratories for the sale and distribution of Amorfix's proprietary antibodies and reagents.

22 Oct 2009

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the publication of a paper in the Journal of Clinical Gastroenterology. The paper reports data using GeneNews' proprietary Sentinel Principle(R) platform technology to identify complex changes in blood gene expression patterns that were differentially regulated between active and inactive Crohn's disease.

22 Oct 2009

Orlando Health implements MedeAnalytics' Clinical Resource Analytics to streamline operational costs

MedeAnalytics, a leading provider of healthcare performance management solutions, announced it has expanded its solution suite at Orlando Health to now include Clinical Resource Analytics.

22 Oct 2009

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter ended September 30, 2009.

22 Oct 2009

ImmunoGen to host a conference call to discuss its financial results

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that will host a conference call at 4:30 pm ET on Thursday, October 29, 2009 to discuss the Company’s financial results for the three-month period ended September 30, 2009 – the first quarter of ImmunoGen’s 2010 fiscal year.

22 Oct 2009

The Melting Pot Restaurants' initiative for cancer research

The Melting Pot Restaurants join St. Jude Children’s Research Hospital in the sixth annual Thanks and Giving campaign from Oct. 31 – Dec. 5 to “give thanks for the healthy kids in your life, and give to those who are not” by donating a portion of proceeds to cancer research.

22 Oct 2009

Peripheral arterial disease linked to lifestyle changes

Modifying the risk of peripheral arterial disease (or PAD)-with healthy lifestyle changes-remains vital to one's health, note researchers in a recent issue of the Journal of Vascular and Interventional Radiology. And while PAD can progress and worsen over time, there is not enough evidence yet to advocate minimally invasive treatment in patients who have had a narrowing or blockage of a leg artery but showing no signs or symptoms of the disease, say Irish researchers in a retrospective study of more than 900 individuals.

22 Oct 2009

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.

22 Oct 2009

San Francisco merchants' initiative for breast cancer research and awareness

Today, the San Francisco Bay Area Affiliate of Susan G. Komen For The Cure announced the launch of the 2009 Shop For The Cure® program, a night of shopping and cocktails hosted by Union Square's finest stores.

22 Oct 2009

Biocare Medical on the 2009 Inc. 5000 list of the fastest-growing private companies in the nation

Inc. magazine has ranked Biocare Medical No. 2984 on the 2009 Inc. 5000 list of the fastest-growing private companies in the nation. The company's sales growth was 93.1% from 2005-2008.

22 Oct 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

LANL and international researchers propose new genome sequence strategies

A team of geneticists at Los Alamos National Laboratory, together with a consortium of international researchers, has recently proposed a set of standards designed to elucidate the quality of publicly available genetic sequencing information.

22 Oct 2009

Researchers develop a new test process for cancer drugs

It is very difficult to predict whether a cancer drug will help an individual patient: only around one third of drugs will work directly in a given patient. Researchers at the Heinz Nixdorf Chair for Medical Electronics at the Technische Universitaet Muenchen (TUM) have developed a new test process for cancer drugs.

22 Oct 2009

HBO treatments may improve neurological outcome after traumatic brain injury

Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced that researchers in its Slavica BioChem division have reported new positive results of experiments in which the potential beneficial effects of Hyperbaric oxygenation (HBO) after traumatic brain injury have been explored.

22 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

New research suggests physical therapy helps restore variety of functions after neurological injury

New research suggests a tailored approach to physical therapy after a neurological injury such as a stroke, traumatic brain injury or spinal cord injury could help restore a wider variety of functions.

22 Oct 2009

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

22 Oct 2009

New health initiative focuses on environmentally-associated cancers

The Barbara Ann Karmanos Cancer Institute, in cooperation with Blue Cross Blue Shield of Michigan (BCBSM), will launch a targeted health initiative in January 2010 focused on environmentally-associated cancers.

22 Oct 2009

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that The Children's Hospital of Philadelphia (CHOP), one of the leading pediatric hospitals and research facilities in the world, has implemented the InforSense-based Translational Research Solution to advance the understanding of complex genetic disease.

22 Oct 2009

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche’s anticancer biologic, Herceptin (trastuzumab).

22 Oct 2009

Cancer News and Research

Latest Cancer News and Research

Amorfix Life Sciences signs sale and distribution agreement with Cedarlane Laboratories

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

Orlando Health implements MedeAnalytics' Clinical Resource Analytics to streamline operational costs

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

ImmunoGen to host a conference call to discuss its financial results

The Melting Pot Restaurants' initiative for cancer research

Peripheral arterial disease linked to lifestyle changes

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

San Francisco merchants' initiative for breast cancer research and awareness

Biocare Medical on the 2009 Inc. 5000 list of the fastest-growing private companies in the nation

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

LANL and international researchers propose new genome sequence strategies

Researchers develop a new test process for cancer drugs

HBO treatments may improve neurological outcome after traumatic brain injury

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

New research suggests physical therapy helps restore variety of functions after neurological injury

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

New health initiative focuses on environmentally-associated cancers

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Cancer Research - Second Edition eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in